In May 2020 it was announced that UrSure had been acquired by Orasure (NASDAQ: OS:UR) - itself an SBIR involved firm. UrSure Inc. is organized around achieving higher levels of adherence to taking medications by usage of noninvasive, painless, cheap urine test: specific focus is on compliance by the patient with their taking the HIV preventive drug, PrEP, More than 1.2 million people in the US at high risk of HIV with about 50,000 infected annually. The medication - PrEP - is 99% effective in preventing HIV BUT requires daily usage - in a population with highlevels of non-adherence. To boost adherence two methods currently available to monitor PrEP levels : both invasive and unpopular with patients. As an alternative, UrSure Inc. has developed a painless, noninvasive - inexpensive - urine- based tests for PrEP. Approach significantly improves improve adherence to PrEP, protecting and empowering patients and physicians to prevent HIV infections.
